Replies to post #212897 on Biotech Values

[WorstLuck]

On June 29, 2017, the Company traded 389,600 shares of its common stock primarily to one investor under the 2016 ATM agreement at a price of $25.56 per share resulting in net proceeds of $9.6 million, after commissions and offering expenses. The cash proceeds were received on July 5, 2017, at which time the transaction settled and common stock was considered issued and outstanding.

Nice price.

[DewDiligence]

RVNC’s net current assets at 9/30/17 were $134.8M (https://www.sec.gov/Archives/edgar/data/1479290/000147929017000042/rvncq31710q.htm#s566245125C215CE2A164C516887ADD48 ). This figure is less than the reported cash figure of $153.4M due to an excess of current liabilities relative to non-cash current assets.

There was no use of the ATM financing facility during 3Q17 other than the previously reported sale of 389K shares @$25.56 (for proceeds of $9.6M) on 7/5/17.